Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose venetoclax plus posaconazole vs standard-dose venetoclax in AML
ChiCTR2100054356Phase 4Not yet recruiting
- Sponsor
- Third People's Hospital of Chengdu
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Third People's Hospital of Chengdu. Primary endpoints: Venetoclax blood concentration, Venetoclax dosage and 1 more. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2100054356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054356.